Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele F Eisenga

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
Kidney International|August 23, 2021
Hypoxia-inducible factor prolyl hydroxylase inhibitor, C-terminal fibroblast growth factor 23 fragments, and hepcidinMichele F Eisenga
The New England Journal of Medicine|December 4, 2023
Ferric Carboxymaltose in Heart Failure with Iron DeficiencyMichele F Eisenga
Critical Care (London, England)|April 13, 2021
Iron Deficiency Defined by Hepcidin in Critically Ill PatientsMichele F Eisenga
The New England Journal of Medicine|February 5, 2025
Lead PoisoningPien Rawee, Michele F Eisenga
Nederlands Tijdschrift Voor Geneeskunde|October 12, 2023
[Hypoxia-inducible factor-prolyl hydroxylase inhibitors: the "alternative" for EPO?]Pien Rawee, Michele F Eisenga
Clinical Kidney Journal|July 22, 2025
Prolonged normothermic perfusion: a promising approach to kidney transplantationMichele F Eisenga, Rainer Oberbauer
The Lancet. Haematology|September 2, 2022
Factors to consider when assessing the IDOCS studyJoanna Sophia J Vinke, Michele F Eisenga
Frontiers in Nephrology|September 7, 2023
Editorial: Personalized medicine in CKD patientsMichele F Eisenga, Gert Mayer, Markus Pirklbauer, et al.
The New England Journal of Medicine|September 12, 2019
Canagliflozin and Renal Outcomes in Diabetic NephropathyAdrian Post, Michele F Eisenga, Stephan J L Bakker
JAMA Internal Medicine|September 6, 2017
Redefining Unexplained Anemia in ElderlyMichele F Eisenga, Suzanne P Stam, Stephan J L Bakker
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
Kidney International|August 23, 2021
Hypoxia-inducible factor prolyl hydroxylase inhibitor, C-terminal fibroblast growth factor 23 fragments, and hepcidinMichele F Eisenga
The New England Journal of Medicine|December 4, 2023
Ferric Carboxymaltose in Heart Failure with Iron DeficiencyMichele F Eisenga
Critical Care (London, England)|April 13, 2021
Iron Deficiency Defined by Hepcidin in Critically Ill PatientsMichele F Eisenga
The New England Journal of Medicine|February 5, 2025
Lead PoisoningPien Rawee, Michele F Eisenga
Nederlands Tijdschrift Voor Geneeskunde|October 12, 2023
[Hypoxia-inducible factor-prolyl hydroxylase inhibitors: the "alternative" for EPO?]Pien Rawee, Michele F Eisenga
Clinical Kidney Journal|July 22, 2025
Prolonged normothermic perfusion: a promising approach to kidney transplantationMichele F Eisenga, Rainer Oberbauer
The Lancet. Haematology|September 2, 2022
Factors to consider when assessing the IDOCS studyJoanna Sophia J Vinke, Michele F Eisenga
Frontiers in Nephrology|September 7, 2023
Editorial: Personalized medicine in CKD patientsMichele F Eisenga, Gert Mayer, Markus Pirklbauer, et al.
The New England Journal of Medicine|September 12, 2019
Canagliflozin and Renal Outcomes in Diabetic NephropathyAdrian Post, Michele F Eisenga, Stephan J L Bakker
JAMA Internal Medicine|September 6, 2017
Redefining Unexplained Anemia in ElderlyMichele F Eisenga, Suzanne P Stam, Stephan J L Bakker
Pageof 12